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Summary: 
pfhrp2 gene deletions render Plasmodium falciparum parasites undetectable to malaria rapid 
diagnostic tests detecting histidine-rich protein 2.  pfhrp2 deletions were detected in archived blood 
samples from Tanzania and Uganda, while no samples from Ghana were found to be pfhpr2-
negative. 
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Abstract: 
Background 
Malaria rapid diagnostic tests (mRDT) that target histidine-rich protein 2 (HRP2) are important tools 
for Plasmodium falciparum diagnosis. Parasites with pfhrp2/3 gene deletions threaten the use of 
these mRDTs, and have been reported in Africa, Asia, and South America. We studied blood samples 
from three African countries to determine if these gene deletions were present.   
Methods 
We analysed 911 dried blood spots from Ghana (165), Tanzania (176) and Uganda (570). P. 
falciparum infection was confirmed by 18SrDNA polymerase-chain reaction (PCR), and pfhrp2/3 
genes were genotyped. True pfhrp2/3 gene deletions were confirmed if samples were (1) 
microscopy positive, (2) 18SrDNA PCR positive, (3) positive for merozoite surface protein genes by 
PCR, or positive by loop-mediated isothermal amplification, and (4) quantitative PCR positive with > 
5 parasites/µl.  
Results 
No pfhrp2/3 deletions were detected in samples from Ghana, but deletions were identified in 
Tanzania (three pfhrp2; two pfhrp3) and Uganda (seven pfhrp2; two pfhrp3). Of the 10 samples with 
pfhrp2 deletions, nine tested negative by HRP2-based mRDT.   
Discussion 
The presence of pfhrp2/3 deletions in Tanzania and Uganda, along with reports of pfhrp2/3-deleted 
parasites in neighbouring countries, reinforces the need for systematic surveillance to monitor the 
reliability of mRDTs in malaria-endemic countries.   
 
Key words: HRP2, HRP3, pfhrp2, pfhrp3, histidine, malaria, rapid diagnostic test, diagnosis, deletion, 
mutation, false-negative, Ghana, Tanzania, Uganda 
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Background 
Prompt and accurate diagnosis of malaria is crucial for malaria case-management and control and 
elimination programmes.  While malaria diagnosis was historically based on symptoms alone, since 
2010 WHO guidelines state that parasite-based diagnosis of malaria should be confirmed before 
treatment is given [1]. While quality-assured microscopy remains the gold standard for diagnosis of 
symptomatic malaria, malaria rapid diagnostic tests (mRDTs), detecting malaria antigen(s), require 
less training, no specialised equipment and play an important role in malaria case-management. The 
use of mRDTs has grown substantially since they were first developed in the 1990s, and mRDTs are 
currently used in the public health care sector in all 91 countries with malaria transmission [2].  
The majority of mRDTs currently on the market detect histidine-rich protein 2 (HRP2), a parasite 
antigen produced throughout the life cycle of Plasmodium falciparum, in a blood sample [3]. In 
general, HRP2-based mRDTs are more sensitive and stable than mRDTs based on other Plasmodium 
antigens, and so are the mRDT of choice in most endemic countries where P. falciparum malaria 
predominates [4].   
The accuracy of HRP2-based mRDTs can be affected by factors including low parasite density (which 
can cause false-negative results), and antigen persisting in the bloodstream after successful 
treatment of a prior clinical episode (which can cause clinically false-positive results). While false-
negative mRDT results have been attributed primarily to the tests’ limit of detection, recent reports 
have confirmed that genetic variation of P. falciparum can also affect mRDT performance [5, 6].  
Over the past decade P. falciparum strains that do not express HRP2 have been documented. The 
first confirmed parasites that lacked the pfhrp2 gene were identified in the Amazon Basin in Peru in 
2010, with 40% of P. falciparum samples testing negative for the gene [7]. Since then, similar 
parasites have been reported from other areas in South America [8, 9], Central America [10], India 
and South-East Asia [11, 12], West Africa [13-15], and East and Central Africa [5, 16-19]. In Africa, the 
highest reported prevalence of pfhrp2 deletions was in Eritrea, where 62% of samples that tested 
positive by microscopy were found to lack the pfhrp2 gene [5]. While fewer studies have confirmed 
pfhrp2 deletions among West African countries, a 2015 study in Ghana showed that 29% of samples 
lacked the pfhrp2 gene [15]. To date, there are  no published reports of pfhrp2 deletions in Tanzania; 
however pfhrp2 deletions were reported in 6.4% of samples from children in Democratic Republic of 
Congo (DRC) [16], and 1% of microscopy-positive samples from a study in Rwanda [18].  An 
unpublished study from Uganda reported 1.7% pfhrp2 deletions among 1,493 microscopy-positive P. 
falciparum samples [20].  Marked heterogeneity in the prevalence of pfhrp2 deletions within and 
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between countries has also been described; the prevalence of pfhrp2 deletions was reported to 
range from 0% to 25% between eight states in India [11], and from 0% to 22% in different regions of 
the DRC [16]. 
Parasites that do not express the HRP2 protein can cause false-negative results by HRP2-based 
mRDTs[6]. The HRP2 protein has an epitope which shows cross-reactivity with HRP3, also expressed 
by P. falciparum. Therefore, HRP2-based mRDTs sometimes detect infections in pfhrp2-deleted 
parasites due to the presence of HRP3, especially at higher parasite densities [21]. However, the 
absence of both HRP2 and HRP3 renders the parasites undetectable by HRP2-based mRDTs.  
As the epidemiology of pfhrp2 and pfhrp3 deletions is still largely unknown, sampling strategies and 
molecular assessment are needed to determine the extent of these deletions in endemic areas, and 
to assess their effect, if any, on routine clinical care of malaria patients. While awaiting the 
implementation of prospective surveillance, this paper reports on stored P. falciparum samples from 
three countries, Ghana, Tanzania, and Uganda.  
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Methods 
This study analysed P. falciparum parasites identified in human blood samples from three malaria 
studies in Ghana, Tanzania and Uganda. For each source study, this analysis included all available 
samples recorded as negative by HRP2-based mRDT and positive by microscopy; plus a random 
selection of available samples recorded as positive by both mRDT and microscopy, of those negative 
by both microscopy and mRDT, and of those positive by mRDT and negative by microscopy. In total 
911 samples were analysed.   
Sample collection 
Samples in Ghana were collected as part of an mRDT clinical evaluation in 2009 and 2010 [22].  
Information about the survey is shown in Table 1. Three hundred and ninety-seven samples were 
collected (Table 2), of which 165 were selected for this study (Figure 1).   
Samples in Tanzania were collected during surveys in 2010 as part of an evaluation of mRDT 
implementation in public health facilities (IMPACT2). Samples were selected from a household 
survey [23] and a health facility survey [24]. In total, 10,535 samples had mRDT and microscopy 
results as well as DBS (Table 2): 8,812 from the household survey and 1,723 from the health facility 
survey. A total of 176 samples were selected for analysis (Figure 1). 
Samples from Uganda were collected as part of the School-Based Treatment with ACT to Reduce 
Transmission (START-IPT) study from 2014 to 2015, a cluster-randomised trial to measure the effects 
of intermittent preventive treatment for malaria [25]. A total of 8,922 microscopy and DBS samples 
were collected from cross-sectional surveys of community residents in control and intervention 
groups (Table 1). mRDTs were performed on participants who were febrile or had history of fever in 
the previous 48 hours. Unique to the Uganda study, loop-mediated isothermal amplification (LAMP) 
for P. falciparum was performed on specified proportions of samples, after DNA extraction from DBS 
by standard methods with Chelex 100 Resin (Bio-Rad, Hercules, CA, USA), resulting in 5,258 samples 
with LAMP results.  Of the samples with microscopy, LAMP and mRDT results, 570 were selected for 
this study (Figure 1).   
Written informed consent was obtained from all participants or participants’ caregivers.  The study 
in Ghana was approved by the Institutional Ethics Committee of the Kintampo Health Research 
Centre and the ethics review committees of the Ghana Health Service. The IMPACT2 study in 
Tanzania was approved by the Institutional Review Board of Ifakara Health Institute.  Ethical 
approval in Uganda was obtained from the Uganda National Council for Science and Technology; 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz335/5524476 by London School of H
ygiene & Tropical M
edicine user on 28 June 2019
Ac
ce
pte
d M
an
us
cri
pt
 
 
Makerere University School of Medicine Research and Ethics Committee; the School of Biological 
and Biomedical Sciences Ethics Committee, Durham University (UK); and the University of California, 
San Francisco Committee on Human Research. All three studies obtained ethics approval from the 
London School of Hygiene and Tropical Medicine (LSHTM).   
Microscopy  
Thick blood smears were stained with 2% or 10% Giemsa and read in duplicate by two microscopists 
who were blinded to the initial reading and to the mRDT results.  Discrepant results were resolved 
by a third microscopist. Parasites were counted against 200 white blood cells and were considered 
negative if no asexual parasites or gametocytes were found after examining 100 fields. Microscopy 
was performed at Kintampo Health Research Centre clinical laboratory in Ghana, Ifakara Health 
Institute, Bagamoyo, in Tanzania, and Makerere University Molecular Research Laboratory, Mulago 
Hospital, Kampala in Uganda.  
Sample storage  
Samples in all three countries were stored in sealed plastic bags with desiccant at ambient 
temperature. Sample were selected in the countries of origin, and DBS from all countries were 
couriered to LSHTM in 2016. Molecular analysis was conducted at LSHTM between October 2016 
and November 2017. 
Molecular analysis 
DNA extraction 
DNA was extracted from all DBS using QIAsymphony according to the manufacturer’s protocol 
(QIAGEN, Germany), using a previously published protocol [21]. A 3mm diameter punch was taken 
from each DBS and placed in a deep well plate. Buffer ATL (180ul) and proteinase (20ul) were added 
to each well and mixed at 900 rpm at 56°C for 15 minutes in a thermomixer. The plates were then 
placed into the QIAsymphony compartments for DNA extraction and the eluted DNA was stored at  
-20°C. 
Amplification of pfhrp2 and pfhrp3  
Parasite presence was confirmed  using standard PCR targeting the 18S ribosomal RNA gene of P. 
falciparum (18SrDNA) as previously published [26]. The limit of detection was 0.1 parasites/µl. For 
samples found positive, genotyping of pfhrp2 and prhrp3 (Genbank accession numbers 
PF3D7_0831800 and PF3D7-1372200 respectively) was then conducted using amended PCR 
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conditions and primers published by Baker, et al. [27].  Briefly, a semi-nested amplification was 
performed using the following conditions: 94°C for 10 minutes, then 94°C for 50 seconds, 50°C for 50 
seconds, and 60°C for 1 minute.  The reaction mixture contained 5 µl of extracted genomic DNA, 
200 nM of each primer, 2 mM of MgCl2, 200 nM of each dNTP, 1X NH4 reaction buffer (Bioline, UK) 
and 1.25U of AmpliTaq Gold (ThermoFisher Scientific, UK). 
Confirmation of pfhrp2 and pfhrp3 deletion 
To confirm the deletion of pfhrp2 and pfhrp3 genes, PCR of two other single copy genes was 
performed. For samples from Ghana and Tanzania, PCR of merozoite surface protein 1 (msp1) and 
msp2 genes was conducted on samples which were pfhrp2-negative using previously-published 
methods [28, 29]. Samples from Uganda had been tested by LAMP [25] and therefore msp 
confirmation was not performed.   
Quantification of parasitemia by qPCR 
The parasitemia of pfhrp2-negative samples was quantified by PgMET qPCR as described in Beshir et 
al., 2010 [30]. The limit of detection for pfhrp2 by this method is 5 parasites/µl [17].  
Classification of pfhrp2/pfhrp3 genes 
Samples were considered to be truly negative for pfhrp2 or pfhrp3 if deletions were identified as 
above and: i) they were positive by microscopy, and ii) they tested positive by 18SrDNA PCR, and iii) 
msp genes were detected by PCR (Ghana, Tanzania) or the sample was positive by LAMP (Uganda). 
Furthermore, only samples above the limit of detection of 5 parasites/µl by qPCR were considered 
true pfhrp2/3-negatives, since samples below this parasite density may have given false-negative 
results by pfhrp2/3 PCR. 
 
Results 
Percentage of samples testing positive for P. falciparum in study samples, by detection method  
Among the samples from Ghana, 107/165 (64.9%) were recorded as positive by mRDT and 82/165 
(49.7%) by microscopy (Figure 2). In Tanzania, 72/171 (53.8%) samples were recorded as positive by 
mRDT, while 140/176 (79.6%) were positive by microscopy (five samples did not have mRDT results). 
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Of the 570 Uganda samples, 258/570 (45.3%) were recorded as positive by mRDT, and 203 (35.6%) 
were positive by microscopy.    
Microscopy and mRDT results for the samples included in this analysis are presented in Figure 1.  
Among the samples available from Ghana, none were recorded as positive by microscopy and 
negative by mRDT. In Tanzania, about one third of the samples selected for analysis were positive by 
microscopy and negative by mRDT (60/171, 35.1%), while in Uganda 125/570 (21.9%) samples were 
recorded as positive by microscopy and negative by RDT.    
Microscopy-determined parasite density in Ghana ranged from 371 to 1,500,000 parasites/µL (mean 
128,505; median 37,960.5). In Tanzania the range was 2 to 9,249 parasites/µl (mean 1,079; median 
60.5). Microscopy-determined parasite densities were not recorded for Uganda samples. 
 
Presence of pfhrp2/pfhrp3 gene deletions 
Of the 165 samples from Ghana, 154 (93.3%) tested positive by 18SrDNA and 80 (48.5%) tested 
positive by both 18SrDNA and microscopy (Figure 3). All 80 samples tested positive for pfhrp2, and 
only one sample tested negative for pfhrp3. No Ghanaian sample was both positive by microscopy 
and negative by mRDT (Table 3). 
Of the 176 samples from Tanzania, 148 (85.1%) were positive by 18SrDNA PCR, of which 137 were 
positive by microscopy. After applying the confirmation criteria for pfhrp2/3 deletions, three 
samples were found to have pfhrp2 deletions. Two samples had pfhrp3 deletions; both of these also 
had pfhrp2 deletions (Table 3). 
Of the 570 samples from Uganda, 416 (73.0%) were positive by PCR, of which 194 were microscopy-
positive. After applying the confirmation criteria seven samples were found to have pfhrp2 
deletions. Two samples had pfhrp3 deletions; both of these were also negative for pfhrp2.    
Overall, nine of the ten pfhrp2-negative samples tested positive by microscopy and negative by 
mRDT (Table 3). Six of these samples had an intact pfhrp3 gene while four did not. One sample from 
Tanzania was positive by both the ICT Diagnostics mRDT and microscopy, and was negative for 
pfhrp3. The parasite concentration of these ten samples ranged from 7.3 to 3,800 parasites/µl by 
qPCR. No sample was negative for pfhrp3 and positive for pfhrp2. 
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Discussion 
P. falciparum parasites lacking the genes coding for histidine-rich proteins, which are detected by 
commonly used mRDTs, pose a threat to malaria control and elimination programmes. This report 
presents an analysis of pfhrp2/3 in archived human blood samples from three African countries, 
alongside microscopy and mRDT results obtained in the primary studies from which the samples 
were drawn. Molecular analysis identified low levels of pfhrp2 and pfhrp3 gene deletions in samples 
from Tanzania (collected in 2010) and Uganda (2014-15), while no evidence of deletions was found 
in samples from Ghana (2009-10).  
Of the ten pfhrp2-negative samples identified in this study, nine were recorded as negative by HRP2-
based mRDT, seven by the mRDT used in Uganda and two by the mRDT in Tanzania. The exception 
was one sample from Tanzania, which was negative for both pfhrp2 and pfhrp3, but positive by 
HRP2-based mRDT; possible explanations for this could be a data recording error, or a false-positive 
mRDT due to cross reactions with human anti-mouse antibodies or rheumatoid factor [31].  All 
mRDTs used in the original studies performed well in the WHO product testing rounds of the 
corresponding study years; however, the panel detection score of the mRDTs used in Uganda and 
Ghana was higher than that of the mRDT used in Tanzania [4, 32], which might explain, at least 
partly, why parasite prevalence by mRDT was lower than by microscopy in Tanzania. Also, most 
samples from Tanzania were from asymptomatic people, while samples from the other two 
countries were from symptomatic patients, resulting in lower parasite density among Tanzanian P. 
falciparum-positive samples.    
Of the nine pfhrp2-negative samples that tested negative by mRDT, six had intact pfhrp3. While it is 
well-documented that HRP2-based mRDTs may give false-negative results in the absence of pfhrp2 
[5, 11, 13], it has also been found that cross reaction with epitopes on HRP3 can produce positive 
mRDT results [7, 15, 27], especially at concentrations above 1,000 parasites/µl [17]. Cross-reactivity 
of HRP3 on HRP2-based RDTs has also been shown to vary between mRDT brands [33]. In this study, 
the parasite densities in the six pfhrp2-negative/ pfhrp3-positive samples ranged from 7.3 to 69.3 
parasites/µl, likely too low to be detected by mRDTs even if HRP3 was present. Parasites with 
deletions in both pfhrp2 and pfhrp3 genes are undetectable by HRP2-based RDTs [34], and therefore 
the presence of pfhrp3 deletions in these populations is significant.   
In this study a true pfhrp2 negative sample was defined as the absence of pfhrp2 in a sample that 
tested positive for malaria by microscopy and positive for P. falciparum either by LAMP or two other 
single copy genes. This produces a conservative estimate of pfhrp2 deletion; some other studies 
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have reported pfhrp2 deletions based only on failure to amplify the pfhrp2 gene by PCR, without also 
confirming parasite presence with two other single copy genes by PCR, which may produce more 
alarming results [8, 9, 35]. We also chose a qPCR cut-off of five parasites/µL, the limit of detection 
for pfhrp2 PCR, to determine true pfhrp2 negative samples [17]. Any samples with a parasite density 
below this threshold may have produced false-negatives for pfhrp2 PCR and could not be confirmed 
as true pfhrp2 negatives. While the majority of published studies have not applied this criterion in 
their identification of pfhrp2 deletions, doing so produces a conservative and more confident 
definition of pfhrp2 deletion [34]. Indeed the number of samples found to be pfhrp2-negative would 
have been higher without this cut-off (Fig 3).  
While this is the first report of pfhrp2 gene deletions in Tanzania, findings from neighbouring 
Rwanda [36], Kenya [21], DRC [16], and nearby Eritrea [5, 19] indicate that the phenomenon is 
present in the region. There are a few reports of pfhrp2 gene deletions in other countries in West 
Africa, including a study using archived samples from Mali [13] and one in Senegal [14].  While our 
study did not show any deletions in Ghana, two other studies in Ghana have reported alarming 
results of 29% [15] and 75% [37] although the latter was among a small sample of only eight 
children.  Samples from the former study were collected in 2015, from Gold Coast and Accra, both in 
the south of the country, while samples from the latter study were collected in Accra, also in 2015.   
Samples in our study were collected in 2010 in Kintampo, in the middle of Ghana, so the differing 
areas and times of sample collection could explain the different findings.  
 Of note, the majority of these studies were not designed specifically to investigate the epidemiology 
of pfhrp2/3 deletions; deletion analysis was conducted on samples that had been collected to 
address other primary objectives, which is also the case for the study reported here. While reports 
of pfhrp2/3 deletions in neighbouring or nearby countries are suggestive, prevalence within a 
geographic area can be highly heterogenous [11, 16], and the design of surveillance efforts should 
take this into account. 
The pfhrp2 gene amino acid sequence and repeats have been shown to vary substantially across 
different geographic regions [38]. This study looked only at presence versus absence of pfhrp2/3 
genes. Genomic sequencing of exons and flanking regions would provide more information on 
sequence diversity among these samples. Even pfhrp2-positive samples may harbour genetic 
diversity with implications for mRDT detection. While diversity in the pfhrp2 gene has not been 
found to affect mRDT affinity in samples with parasite densities of clinical significance [11, 39], it has 
been shown to affect mRDT results at densities below 200 parasites per µL[27].  
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz335/5524476 by London School of H
ygiene & Tropical M
edicine user on 28 June 2019
Ac
ce
pte
d M
an
us
cri
pt
 
 
The phenomenon of pfhrp2/3 gene deletions poses a substantial threat to malaria control and could 
reverse the gains made through the rapid expansion of mRDT uptake over the past decade [40]. 
Prescriber adherence to test results, especially negative test results, has been a key focus of mRDT 
implementation efforts to date [41, 42]. False-negative mRDT results lead to under-diagnosis of 
malaria, and if patients who are infected but test negative do not receive antimalarial treatment, 
severe disease and even death may result; and the pfhrp2-deleted parasites in their bloodstream 
may then be taken up by female Anopheles mosquitoes and transmitted to others [6]. Models have 
demonstrated that newly introduced pfhrp2-negative parasites can spread rapidly though a 
community if HRP2-based mRDTs are the only diagnostic tool used to guide treatment practices [40]. 
Using publicly available genomic data generated from genetic crosses, the absence of fitness cost for 
hrp2-negative parasites has recently been reported [43]. 
In malaria-endemic countries, assessment and surveillance of pfhrp2/3 deletions and their impact 
must be undertaken effectively and efficiently, alongside multiple other public health and malaria 
control priorities. To this end, WHO has published a protocol for implementing surveys designed to 
measure pfhrp2-deleted parasites among malaria suspects [44]. WHO guidelines state that if the 
prevalence of pfhrp2 gene deletions that cause false-negative HRP2-based RDT results in a 
representative sample is higher than 5%, HRP2-based mRDTs should be replaced with a new 
diagnostic tool [44]. In such cases mRDTs that target other antigens, such as those detecting pan-
LDH or Pf-pLDH, may be considered. However, pLDH-based mRDTs are generally less sensitive and 
heat stable than HRP2-based RDTs and this trade-off must be weighed in considering a switch. The 
5% threshold in the WHO guidance is estimated to be the prevalence at which the benefits of non-
HRP2-based diagnostics for detecting pfhrp2-deleted parasites outweighs the reduced sensitivity of 
these tools to detect wild-type parasites. 
This study has several limitations. The blood samples analysed were collected as part of other 
malaria studies which were not designed to study pfhrp2/3 deletions nor to measure prevalence of 
these mutations. DBS samples were purposively selected from the available samples and were not 
representative of the total original study populations. Furthermore the samples were taken from 
different human populations, including a household survey of asymptomatic individuals and exit 
interviews of febrile patients who sought care at health facilities; in Ghana these surveys targeted 
children while in Tanzania and Uganda they targeted individuals of all ages. Samples were collected 
at different time points, from 2010 in Ghana to 2015 in Uganda, which may affect the findings if the 
epidemiology of gene deletions has changed over time. This makes it impossible to directly compare 
results across the three countries. Samples had been stored for several years before molecular 
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analysis in non-refrigerated conditions, however, a set of criteria were followed to determine 
pfhrp2/3 deletions to compensate for this.  This molecular analysis focussed on exon 2, as this is the 
main part of the gene that affects RDT performance.  However also targeting the region across exon 
1 and flanking genes would provide greater confirmatory evidence of gene deletions and enable 
detection of partial gene deletions on chromosome breaking points. Rather than measuring 
prevalence of gene deletions, this study serves as one indicator, using rigorous laboratory methods 
to determine whether any mutated parasites are present in available samples from the study areas.  
This report documents the presence of pfhrp2/3 gene deletions in P. falciparum in archived blood 
samples from two East African countries, Tanzania and Uganda. Further studies and surveillance will 
be essential to better understand the epidemiology of these parasites, as well as to guide future 
decisions about diagnostic tools and strategies. Although no conclusions about the prevalence of 
pfhrp2/3 deletions can be drawn from this study, the fact that only a few deleted parasites were 
identified suggests that HRP2-based mRDTs are still a valid diagnostic tool in these countries. 
However, together with other reports documenting the presence and potential spread of such 
parasites in nearby areas, this study reinforces the WHO call for systematic surveillance to monitor 
the reliability of mRDTs [44]. 
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Table 1.  Characteristics of primary studies from which dried blood spot samples were selected for analysis of pfhrp2 and pfhrp3 
Country Type of 
survey 
Date of 
sample 
collection 
Study sites Clinical status of 
participants 
Age range of 
participants 
mRDT 
manufacturer 
Estimated 
entomological 
inoculation rate 
Reference of 
study from 
which 
samples 
were 
collected 
Ghana Health facility 2009 - 2010 Kintampo Symptomatic Children aged 
6 – 30 months 
CareStart (Access 
Bio) 
269 a Baiden et al 
[22] 
Tanzania Household, 
health facility 
2010 Mbeya, 
Mtwara and 
Mwanza 
regions 
Asymptomatic 
and symptomatic 
All ages from 
six months and 
above 
ICT Diagnostics 10.4-148.6b Thomson et 
al [23], 
Bruxvoort et 
al, [24] 
Uganda Cross-
sectional 
2014 - 2015 Jinja district Symptomaticc All ages CareStart (Access 
Bio) 
(Somerset, NJ) 
56.3-61.5 Staedke et al 
[25] 
mRDT = malaria rapid diagnostic test. 
a
The entomological inoculation rate was not assessed in the Ghana study.  Data are from Owusu-Agyei S, Asante KP, Adjuik M, Adjei G, Awini E, Adams M, et al. 
Epidemiology of malaria in the forest-savanna transitional zone of Ghana. Malaria journal. 2009;8:220. Epub 2009/09/30. doi: 10.1186/1475-2875-8-220. PubMed 
PMID: 19785766; PubMed Central PMCID: PMCPMC2765449. 
b
The entomological inoculation rate was not assessed in the Tanzania study.  A range of values are presented as the study in Tanzania was conducted in three different 
regions with varying malaria transmission. Data are from Maxwell CA, Chambo W, Mwaimu M, Magogo F, Carneiro IA, Curtis CF. Variation of malaria transmission and 
morbidity with altitude in Tanzania and with introduction of alphacypermethrin treated nets. Malaria journal. 2003;2:28. Epub 2003/10/31. doi: 10.1186/1475-2875-2-
28. PubMed PMID: 14585106; PubMed Central PMCID: PMCPMC239954. 
c
The survey in Uganda was conducted on symptomatic and asymptomatic people, but malaria rapid diagnostic tests were performed only on symptomatic participants and 
therefore samples for this study were from symptomatic people. 
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Table 2.  Study populations from which dried blood spot samples were selected for analysis of pfhrp2 and pfhrp3 
 
Study site 
mRDT negative, 
microscopy 
negative 
mRDT negative, 
microscopy 
positive 
mRDT positive, 
microscopy 
negative 
mRDT positive, 
microscopy 
positive 
Ghana 148 0 58 191 
Tanzania 8,319 102 1,663 451 
Uganda 2,508 122 1,395 1,235 
mRDT = malaria rapid diagnostic test. 
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Table 3. Samples with pfhrp2 and pfhrp3 deletions among PCR-positive P. falciparum samples, by country of origin and results of microscopy and HRP2-
based malaria rapid diagnostic test  
   
 mRDT negative, 
microscopy 
negative 
mRDT negative, 
microscopy 
positive 
mRDT positive, 
microscopy 
negative 
mRDT positive, 
microscopy 
positive 
Number of PCR positive samples among all samples analysed 
Ghana 50  0 24 80 
Tanzania 7 57 4 75 
Uganda 176 116 46 78 
pfhrp gene deletion status among PCR positive samples 
Ghana     
No deletion 50 0 24 80 
pfhrp2-/ pfhrp3+ 0 0 0 0 
pfhrp2+/ pfhrp3- 0 0 0 0 
pfhrp2-/ pfhrp3- 0 0 0 0 
Tanzania 
No deletion 7 55 4 74 
pfhrp2-/ pfhrp3+ 0 1 0 0 
pfhrp2+/ pfhrp3- 0 0 0 0 
pfhrp2-/ pfhrp3- 0 1 0 1 
Uganda 
No deletion 176 109 46 78 
pfhrp2-/ pfhrp3+ 0 5 0 0 
pfhrp2+/ pfhrp3- 0 0 0 0 
pfhrp2-/ pfhrp3- 0 2 0 0 
mRDT = malaria rapid diagnostic test. 
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Figure 1. Two-by-two tables showing results of malaria rapid diagnostic tests (mRDT) based on 
detection of histidine-rich protein 2 (HRP2) and expert microscopy for human blood samples 
analysed for pfhrp2/3 genes 
 
a Five samples from Tanzania had no corresponding mRDT result. 
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Figure 2.  Percentage of samples positive for P. falciparum in study samples, by detection method 
 
mRDT = malaria rapid diagnostic test. 
PCR = polymerase chain reaction. 
*denotes kappa value of 0.6 or higher, indicating good agreement between diagnostic methods.  
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Figure 3.  Flow diagram showing process of determining pfhrp2 and pfhrp3 gene deletion in blood 
samples from studies in three African countries 
 
 
PCR = polymerase chain reaction 
msp = merozoite surface protein 
LAMP = loop mediated isothermal amplification 
qPCR = quantitative polymerase chain reaction 
*The first number in each row denotes the number of samples among pfhrp2-negative samples; the 
second denotes the number among pfhrp3-negative samples. 
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